Akums Receives Nod for Triple Combination Diabetes Treatment

Akums Drugs and Pharmaceuticals Limited's triple combination diabetic treatment has been approved. Sitagliptin 100, Pioglitazone 15, and Metformin 1000/500 are more advanced diabetes treatments with far more efficacy and precision than currently available monotherapy medicines. Sitagliptin 100, Pioglitazone 15, and Metformin 1000/500 are specifically designed for the treatment of diabetes and provide a number of pharmacological benefits.

Metformin, a glucose-lowering medication commonly used as first-line therapy for type 2 diabetes (T2D), is one of three unique active formulations in the combination. Pioglitazone, on the other hand, is a standout component because of its capacity to improve insulin sensitivity, lower HbA1c levels, and promote lipid metabolism and insulin secretion. Sitagliptin, the third component of the combo, has been shown to dramatically lower HbA(1c) levels when administered as an add-on therapy following insulin, sulfonylureas, or thiazolidinediones, or alone with or without Metformin.

We thoroughly examined the pharmacological features of various formulations and discovered the ideal blend for our triple-active combination of Sitagliptin 100, Pioglitazone 15, and Metamorfin 1000/500. This will benefit diabetes individuals who need better treatment without having to take many medications. The approval is significant because it demonstrates that we followed all procedures and that the drug is suitable for use by patients who require relief from the effects of not only type 2 diabetes, but also patient convenience and dosage compliance," said Sanjeev Jain, Jt Managing Director, Akums Drugs & Pharmaceuticals.

The bi-layered combination was formulated following well-researched processes and operations and adherence to pharmacological guidelines. Speaking on the approval, Sandeep Jain, Jt Managing Director, Akums Drugs & Pharmaceuticals, noted that the renoprotective effects of drugs like Metformin coupled with the functional and corrective influence of Pioglitazone on beta-cell and metabolic syndrome, and the stability of Sitagliptin, make an effective solution for diabetes. The company aims to penetrate the market with innovative, safe, and high-quality pharma solutions.